Corpus
PascalFrancis
Racine
Corpus
Checkpoint
PascalFrancis
Racine
PascalFrancis
Exploration
Accueil
Racine
Racine

Movement Disorders (revue)

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Comparison of standard carbidopa-levodopa and sustained-release carbidopa-levodopa in Parkinson's disease : Pharmacokinetic and quality-of-life measures

Identifieur interne : 003192 ( PascalFrancis/Corpus ); précédent : 003191; suivant : 003193

Comparison of standard carbidopa-levodopa and sustained-release carbidopa-levodopa in Parkinson's disease : Pharmacokinetic and quality-of-life measures

Auteurs : R. Pahwa ; K. Lyons ; D. Mcguire ; P. Silverstein ; F. Zwiebel ; M. Robischon ; W. C. Koller

Source :

RBID : Pascal:97-0489601

Descripteurs français

English descriptors

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

pA  
A01 01  1    @0 0885-3185
A03   1    @0 Mov. disord.
A05       @2 12
A06       @2 5
A08 01  1  ENG  @1 Comparison of standard carbidopa-levodopa and sustained-release carbidopa-levodopa in Parkinson's disease : Pharmacokinetic and quality-of-life measures
A11 01  1    @1 PAHWA (R.)
A11 02  1    @1 LYONS (K.)
A11 03  1    @1 MCGUIRE (D.)
A11 04  1    @1 SILVERSTEIN (P.)
A11 05  1    @1 ZWIEBEL (F.)
A11 06  1    @1 ROBISCHON (M.)
A11 07  1    @1 KOLLER (W. C.)
A14 01      @1 Department of Neurology, University of Kansas Medical Center @2 Kansas City, Kansas @3 USA @Z 1 aut. @Z 2 aut. @Z 3 aut. @Z 7 aut.
A14 02      @1 Parkinson's Disease Clinic, Methodist Hospital @2 St. Louis Park, Minnesota @3 USA @Z 4 aut. @Z 5 aut. @Z 6 aut.
A20       @1 677-681
A21       @1 1997
A23 01      @0 ENG
A43 01      @1 INIST @2 20953 @5 354000069259610070
A44       @0 0000 @1 © 1997 INIST-CNRS. All rights reserved.
A45       @0 20 ref.
A47 01  1    @0 97-0489601
A60       @1 P
A61       @0 A
A64 01  1    @0 Movement disorders
A66 01      @0 USA
C02 01  X    @0 002B02B06
C03 01  X  FRE  @0 Parkinson maladie @5 01
C03 01  X  ENG  @0 Parkinson disease @5 01
C03 01  X  SPA  @0 Parkinson enfermedad @5 01
C03 02  X  FRE  @0 Carbidopa @2 NK @2 FR @5 04
C03 02  X  ENG  @0 Carbidopa @2 NK @2 FR @5 04
C03 02  X  SPA  @0 Carbidopa @2 NK @2 FR @5 04
C03 03  X  FRE  @0 Antiparkinsonien @5 05
C03 03  X  ENG  @0 Antiparkinson agent @5 05
C03 03  X  SPA  @0 Antiparkinsoniano @5 05
C03 04  X  FRE  @0 Lévodopa @5 07
C03 04  X  ENG  @0 Levodopa @5 07
C03 04  X  SPA  @0 Levodopa @5 07
C03 05  X  FRE  @0 Chimiothérapie @5 16
C03 05  X  ENG  @0 Chemotherapy @5 16
C03 05  X  SPA  @0 Quimioterapia @5 16
C03 06  X  FRE  @0 Traitement @5 17
C03 06  X  ENG  @0 Treatment @5 17
C03 06  X  GER  @0 Aufbereiten @5 17
C03 06  X  SPA  @0 Tratamiento @5 17
C03 07  X  FRE  @0 Homme @5 20
C03 07  X  ENG  @0 Human @5 20
C03 07  X  SPA  @0 Hombre @5 20
C03 08  X  FRE  @0 Etude comparative @5 23
C03 08  X  ENG  @0 Comparative study @5 23
C03 08  X  GER  @0 Vergleich @5 23
C03 08  X  SPA  @0 Estudio comparativo @5 23
C03 09  X  FRE  @0 Forme libération contrôlée @5 24
C03 09  X  ENG  @0 Controlled release form @5 24
C03 09  X  SPA  @0 Forma liberación controlada @5 24
C03 10  X  FRE  @0 Qualité vie @5 35
C03 10  X  ENG  @0 Quality of life @5 35
C03 10  X  SPA  @0 Calidad vida @5 35
C03 11  X  FRE  @0 Pharmacocinétique @5 36
C03 11  X  ENG  @0 Pharmacokinetics @5 36
C03 11  X  SPA  @0 Farmacocinética @5 36
C07 01  X  FRE  @0 Système nerveux pathologie @5 37
C07 01  X  ENG  @0 Nervous system diseases @5 37
C07 01  X  SPA  @0 Sistema nervioso patología @5 37
C07 02  X  FRE  @0 Système nerveux central pathologie @5 38
C07 02  X  ENG  @0 Central nervous system disease @5 38
C07 02  X  SPA  @0 Sistema nervosio central patología @5 38
C07 03  X  FRE  @0 Encéphale pathologie @5 39
C07 03  X  ENG  @0 Cerebral disorder @5 39
C07 03  X  SPA  @0 Encéfalo patología @5 39
C07 04  X  FRE  @0 Extrapyramidal syndrome @5 40
C07 04  X  ENG  @0 Extrapyramidal syndrome @5 40
C07 04  X  SPA  @0 Extrapiramidal síndrome @5 40
C07 05  X  FRE  @0 Maladie dégénérative @5 41
C07 05  X  ENG  @0 Degenerative disease @5 41
C07 05  X  SPA  @0 Enfermedad degenerativa @5 41
N21       @1 300

Format Inist (serveur)

NO : PASCAL 97-0489601 INIST
ET : Comparison of standard carbidopa-levodopa and sustained-release carbidopa-levodopa in Parkinson's disease : Pharmacokinetic and quality-of-life measures
AU : PAHWA (R.); LYONS (K.); MCGUIRE (D.); SILVERSTEIN (P.); ZWIEBEL (F.); ROBISCHON (M.); KOLLER (W. C.)
AF : Department of Neurology, University of Kansas Medical Center/Kansas City, Kansas/Etats-Unis (1 aut., 2 aut., 3 aut., 7 aut.); Parkinson's Disease Clinic, Methodist Hospital/St. Louis Park, Minnesota/Etats-Unis (4 aut., 5 aut., 6 aut.)
DT : Publication en série; Niveau analytique
SO : Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 1997; Vol. 12; No. 5; Pp. 677-681; Bibl. 20 ref.
LA : Anglais
CC : 002B02B06
FD : Parkinson maladie; Carbidopa; Antiparkinsonien; Lévodopa; Chimiothérapie; Traitement; Homme; Etude comparative; Forme libération contrôlée; Qualité vie; Pharmacocinétique
FG : Système nerveux pathologie; Système nerveux central pathologie; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative
ED : Parkinson disease; Carbidopa; Antiparkinson agent; Levodopa; Chemotherapy; Treatment; Human; Comparative study; Controlled release form; Quality of life; Pharmacokinetics
EG : Nervous system diseases; Central nervous system disease; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease
GD : Aufbereiten; Vergleich
SD : Parkinson enfermedad; Carbidopa; Antiparkinsoniano; Levodopa; Quimioterapia; Tratamiento; Hombre; Estudio comparativo; Forma liberación controlada; Calidad vida; Farmacocinética
LO : INIST-20953.354000069259610070
ID : 97-0489601

Links to Exploration step

Pascal:97-0489601

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en" level="a">Comparison of standard carbidopa-levodopa and sustained-release carbidopa-levodopa in Parkinson's disease : Pharmacokinetic and quality-of-life measures</title>
<author>
<name sortKey="Pahwa, R" sort="Pahwa, R" uniqKey="Pahwa R" first="R." last="Pahwa">R. Pahwa</name>
<affiliation>
<inist:fA14 i1="01">
<s1>Department of Neurology, University of Kansas Medical Center</s1>
<s2>Kansas City, Kansas</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Lyons, K" sort="Lyons, K" uniqKey="Lyons K" first="K." last="Lyons">K. Lyons</name>
<affiliation>
<inist:fA14 i1="01">
<s1>Department of Neurology, University of Kansas Medical Center</s1>
<s2>Kansas City, Kansas</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Mcguire, D" sort="Mcguire, D" uniqKey="Mcguire D" first="D." last="Mcguire">D. Mcguire</name>
<affiliation>
<inist:fA14 i1="01">
<s1>Department of Neurology, University of Kansas Medical Center</s1>
<s2>Kansas City, Kansas</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Silverstein, P" sort="Silverstein, P" uniqKey="Silverstein P" first="P." last="Silverstein">P. Silverstein</name>
<affiliation>
<inist:fA14 i1="02">
<s1>Parkinson's Disease Clinic, Methodist Hospital</s1>
<s2>St. Louis Park, Minnesota</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Zwiebel, F" sort="Zwiebel, F" uniqKey="Zwiebel F" first="F." last="Zwiebel">F. Zwiebel</name>
<affiliation>
<inist:fA14 i1="02">
<s1>Parkinson's Disease Clinic, Methodist Hospital</s1>
<s2>St. Louis Park, Minnesota</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Robischon, M" sort="Robischon, M" uniqKey="Robischon M" first="M." last="Robischon">M. Robischon</name>
<affiliation>
<inist:fA14 i1="02">
<s1>Parkinson's Disease Clinic, Methodist Hospital</s1>
<s2>St. Louis Park, Minnesota</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Koller, W C" sort="Koller, W C" uniqKey="Koller W" first="W. C." last="Koller">W. C. Koller</name>
<affiliation>
<inist:fA14 i1="01">
<s1>Department of Neurology, University of Kansas Medical Center</s1>
<s2>Kansas City, Kansas</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">INIST</idno>
<idno type="inist">97-0489601</idno>
<date when="1997">1997</date>
<idno type="stanalyst">PASCAL 97-0489601 INIST</idno>
<idno type="RBID">Pascal:97-0489601</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">003192</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en" level="a">Comparison of standard carbidopa-levodopa and sustained-release carbidopa-levodopa in Parkinson's disease : Pharmacokinetic and quality-of-life measures</title>
<author>
<name sortKey="Pahwa, R" sort="Pahwa, R" uniqKey="Pahwa R" first="R." last="Pahwa">R. Pahwa</name>
<affiliation>
<inist:fA14 i1="01">
<s1>Department of Neurology, University of Kansas Medical Center</s1>
<s2>Kansas City, Kansas</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Lyons, K" sort="Lyons, K" uniqKey="Lyons K" first="K." last="Lyons">K. Lyons</name>
<affiliation>
<inist:fA14 i1="01">
<s1>Department of Neurology, University of Kansas Medical Center</s1>
<s2>Kansas City, Kansas</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Mcguire, D" sort="Mcguire, D" uniqKey="Mcguire D" first="D." last="Mcguire">D. Mcguire</name>
<affiliation>
<inist:fA14 i1="01">
<s1>Department of Neurology, University of Kansas Medical Center</s1>
<s2>Kansas City, Kansas</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Silverstein, P" sort="Silverstein, P" uniqKey="Silverstein P" first="P." last="Silverstein">P. Silverstein</name>
<affiliation>
<inist:fA14 i1="02">
<s1>Parkinson's Disease Clinic, Methodist Hospital</s1>
<s2>St. Louis Park, Minnesota</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Zwiebel, F" sort="Zwiebel, F" uniqKey="Zwiebel F" first="F." last="Zwiebel">F. Zwiebel</name>
<affiliation>
<inist:fA14 i1="02">
<s1>Parkinson's Disease Clinic, Methodist Hospital</s1>
<s2>St. Louis Park, Minnesota</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Robischon, M" sort="Robischon, M" uniqKey="Robischon M" first="M." last="Robischon">M. Robischon</name>
<affiliation>
<inist:fA14 i1="02">
<s1>Parkinson's Disease Clinic, Methodist Hospital</s1>
<s2>St. Louis Park, Minnesota</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Koller, W C" sort="Koller, W C" uniqKey="Koller W" first="W. C." last="Koller">W. C. Koller</name>
<affiliation>
<inist:fA14 i1="01">
<s1>Department of Neurology, University of Kansas Medical Center</s1>
<s2>Kansas City, Kansas</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series>
<title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint>
<date when="1997">1997</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt>
<title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Antiparkinson agent</term>
<term>Carbidopa</term>
<term>Chemotherapy</term>
<term>Comparative study</term>
<term>Controlled release form</term>
<term>Human</term>
<term>Levodopa</term>
<term>Parkinson disease</term>
<term>Pharmacokinetics</term>
<term>Quality of life</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr">
<term>Parkinson maladie</term>
<term>Carbidopa</term>
<term>Antiparkinsonien</term>
<term>Lévodopa</term>
<term>Chimiothérapie</term>
<term>Traitement</term>
<term>Homme</term>
<term>Etude comparative</term>
<term>Forme libération contrôlée</term>
<term>Qualité vie</term>
<term>Pharmacocinétique</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
</TEI>
<inist>
<standard h6="B">
<pA>
<fA01 i1="01" i2="1">
<s0>0885-3185</s0>
</fA01>
<fA03 i2="1">
<s0>Mov. disord.</s0>
</fA03>
<fA05>
<s2>12</s2>
</fA05>
<fA06>
<s2>5</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG">
<s1>Comparison of standard carbidopa-levodopa and sustained-release carbidopa-levodopa in Parkinson's disease : Pharmacokinetic and quality-of-life measures</s1>
</fA08>
<fA11 i1="01" i2="1">
<s1>PAHWA (R.)</s1>
</fA11>
<fA11 i1="02" i2="1">
<s1>LYONS (K.)</s1>
</fA11>
<fA11 i1="03" i2="1">
<s1>MCGUIRE (D.)</s1>
</fA11>
<fA11 i1="04" i2="1">
<s1>SILVERSTEIN (P.)</s1>
</fA11>
<fA11 i1="05" i2="1">
<s1>ZWIEBEL (F.)</s1>
</fA11>
<fA11 i1="06" i2="1">
<s1>ROBISCHON (M.)</s1>
</fA11>
<fA11 i1="07" i2="1">
<s1>KOLLER (W. C.)</s1>
</fA11>
<fA14 i1="01">
<s1>Department of Neurology, University of Kansas Medical Center</s1>
<s2>Kansas City, Kansas</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="02">
<s1>Parkinson's Disease Clinic, Methodist Hospital</s1>
<s2>St. Louis Park, Minnesota</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</fA14>
<fA20>
<s1>677-681</s1>
</fA20>
<fA21>
<s1>1997</s1>
</fA21>
<fA23 i1="01">
<s0>ENG</s0>
</fA23>
<fA43 i1="01">
<s1>INIST</s1>
<s2>20953</s2>
<s5>354000069259610070</s5>
</fA43>
<fA44>
<s0>0000</s0>
<s1>© 1997 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45>
<s0>20 ref.</s0>
</fA45>
<fA47 i1="01" i2="1">
<s0>97-0489601</s0>
</fA47>
<fA60>
<s1>P</s1>
</fA60>
<fA61>
<s0>A</s0>
</fA61>
<fA64 i1="01" i2="1">
<s0>Movement disorders</s0>
</fA64>
<fA66 i1="01">
<s0>USA</s0>
</fA66>
<fC02 i1="01" i2="X">
<s0>002B02B06</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE">
<s0>Parkinson maladie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG">
<s0>Parkinson disease</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA">
<s0>Parkinson enfermedad</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE">
<s0>Carbidopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG">
<s0>Carbidopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA">
<s0>Carbidopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE">
<s0>Antiparkinsonien</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG">
<s0>Antiparkinson agent</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA">
<s0>Antiparkinsoniano</s0>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE">
<s0>Lévodopa</s0>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG">
<s0>Levodopa</s0>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA">
<s0>Levodopa</s0>
<s5>07</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE">
<s0>Chimiothérapie</s0>
<s5>16</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG">
<s0>Chemotherapy</s0>
<s5>16</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA">
<s0>Quimioterapia</s0>
<s5>16</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE">
<s0>Traitement</s0>
<s5>17</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG">
<s0>Treatment</s0>
<s5>17</s5>
</fC03>
<fC03 i1="06" i2="X" l="GER">
<s0>Aufbereiten</s0>
<s5>17</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA">
<s0>Tratamiento</s0>
<s5>17</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE">
<s0>Homme</s0>
<s5>20</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG">
<s0>Human</s0>
<s5>20</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA">
<s0>Hombre</s0>
<s5>20</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE">
<s0>Etude comparative</s0>
<s5>23</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG">
<s0>Comparative study</s0>
<s5>23</s5>
</fC03>
<fC03 i1="08" i2="X" l="GER">
<s0>Vergleich</s0>
<s5>23</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA">
<s0>Estudio comparativo</s0>
<s5>23</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE">
<s0>Forme libération contrôlée</s0>
<s5>24</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG">
<s0>Controlled release form</s0>
<s5>24</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA">
<s0>Forma liberación controlada</s0>
<s5>24</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE">
<s0>Qualité vie</s0>
<s5>35</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG">
<s0>Quality of life</s0>
<s5>35</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA">
<s0>Calidad vida</s0>
<s5>35</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE">
<s0>Pharmacocinétique</s0>
<s5>36</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG">
<s0>Pharmacokinetics</s0>
<s5>36</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA">
<s0>Farmacocinética</s0>
<s5>36</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE">
<s0>Système nerveux pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG">
<s0>Nervous system diseases</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA">
<s0>Sistema nervioso patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE">
<s0>Système nerveux central pathologie</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG">
<s0>Central nervous system disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA">
<s0>Sistema nervosio central patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE">
<s0>Encéphale pathologie</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG">
<s0>Cerebral disorder</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA">
<s0>Encéfalo patología</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE">
<s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG">
<s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA">
<s0>Extrapiramidal síndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE">
<s0>Maladie dégénérative</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG">
<s0>Degenerative disease</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA">
<s0>Enfermedad degenerativa</s0>
<s5>41</s5>
</fC07>
<fN21>
<s1>300</s1>
</fN21>
</pA>
</standard>
<server>
<NO>PASCAL 97-0489601 INIST</NO>
<ET>Comparison of standard carbidopa-levodopa and sustained-release carbidopa-levodopa in Parkinson's disease : Pharmacokinetic and quality-of-life measures</ET>
<AU>PAHWA (R.); LYONS (K.); MCGUIRE (D.); SILVERSTEIN (P.); ZWIEBEL (F.); ROBISCHON (M.); KOLLER (W. C.)</AU>
<AF>Department of Neurology, University of Kansas Medical Center/Kansas City, Kansas/Etats-Unis (1 aut., 2 aut., 3 aut., 7 aut.); Parkinson's Disease Clinic, Methodist Hospital/St. Louis Park, Minnesota/Etats-Unis (4 aut., 5 aut., 6 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 1997; Vol. 12; No. 5; Pp. 677-681; Bibl. 20 ref.</SO>
<LA>Anglais</LA>
<CC>002B02B06</CC>
<FD>Parkinson maladie; Carbidopa; Antiparkinsonien; Lévodopa; Chimiothérapie; Traitement; Homme; Etude comparative; Forme libération contrôlée; Qualité vie; Pharmacocinétique</FD>
<FG>Système nerveux pathologie; Système nerveux central pathologie; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative</FG>
<ED>Parkinson disease; Carbidopa; Antiparkinson agent; Levodopa; Chemotherapy; Treatment; Human; Comparative study; Controlled release form; Quality of life; Pharmacokinetics</ED>
<EG>Nervous system diseases; Central nervous system disease; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease</EG>
<GD>Aufbereiten; Vergleich</GD>
<SD>Parkinson enfermedad; Carbidopa; Antiparkinsoniano; Levodopa; Quimioterapia; Tratamiento; Hombre; Estudio comparativo; Forma liberación controlada; Calidad vida; Farmacocinética</SD>
<LO>INIST-20953.354000069259610070</LO>
<ID>97-0489601</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003192 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 003192 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:97-0489601
   |texte=   Comparison of standard carbidopa-levodopa and sustained-release carbidopa-levodopa in Parkinson's disease : Pharmacokinetic and quality-of-life measures
}}
Wicri

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024